What is Geodon (ziprasidone) used for, and what are its dosing recommendations, contraindications, and common side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Geodon (Ziprasidone): Clinical Overview

Geodon (ziprasidone) is an atypical antipsychotic FDA-approved for treating schizophrenia and acute manic or mixed episodes of bipolar disorder in adults, with maintenance therapy approval when combined with lithium or valproate. 1

FDA-Approved Indications

Ziprasidone is approved for:

  • Schizophrenia (oral and intramuscular formulations)
  • Acute manic or mixed episodes associated with bipolar disorder 1
  • Maintenance treatment of bipolar disorder when added to lithium or valproate 1
  • Available as both oral capsules and short-acting intramuscular injection 2

Dosing Recommendations

Oral Dosing

The target therapeutic dose range is 120-160 mg/day divided into two doses, as only these doses have demonstrated superiority over placebo 3, 4.

  • Initial dosing: 40-80 mg twice daily
  • Therapeutic range: 120-160 mg/day (divided BID)
  • Maximum approved dose: 160 mg/day 5, 3

Critical dosing requirement: Ziprasidone MUST be taken with food containing at least 500 kcal 3. Without adequate food intake, absorption is substantially reduced and cannot be compensated for by increasing the dose—this is a common pitfall that undermines treatment effectiveness 3.

Intramuscular Dosing

  • 10-20 mg IM as needed for acute agitation
  • Maximum: 40 mg/day for up to 3 consecutive days only 5

Absolute Contraindications

Do not prescribe ziprasidone if the patient has: 1

  • Cardiac conditions: Long QT syndrome, recent myocardial infarction, severe heart failure, or arrhythmias
  • Concurrent QT-prolonging medications: Including dofetilide, sotalol, quinidine, Class Ia/III antiarrhythmics, thioridazine, chlorpromazine, droperidol, pimozide, certain fluoroquinolones (sparfloxacin, gatifloxacin, moxifloxacin), halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron, probucol, or tacrolimus
  • Current MAOI use or within 14 days of discontinuation
  • Known allergy to ziprasidone
  • Dementia-related psychosis (black box warning: increased mortality risk) 1

Common Side Effects

The most frequent adverse events include 6:

Highest risk (by risk difference):

  • Somnolence (21% incidence; 14% attributable to drug)
  • Extrapyramidal symptoms (13% incidence; 6% attributable to drug)
  • Asthenia (5% attributable to drug)
  • Weight gain (4% attributable to drug)
  • Dizziness (4% attributable to drug)
  • Dyspepsia (4% attributable to drug)

Other common effects:

  • Nausea and constipation 1
  • Restlessness and abnormal muscle movements 1
  • Diarrhea and rash 1

Critical Safety Warnings

QTc Prolongation

Ziprasidone causes QTc prolongation averaging 20 msec 4, which is more than other atypical antipsychotics 1. While this has not translated into significant clinical arrhythmias in trials (only 0.06% had QTc >500 msec) 4, this relegates ziprasidone to consideration after assessing cardiac risk versus benefits of alternative agents 1, 3.

Before prescribing, obtain:

  • Baseline ECG
  • Electrolytes (potassium, magnesium)
  • Complete cardiac history including family history
  • Comprehensive medication review for drug interactions 1

Life-Threatening Conditions to Monitor

Neuroleptic Malignant Syndrome (NMS): Presents with high fever, rigid muscles, confusion, sweating, tachycardia, and hypertension—requires immediate discontinuation 1

Serotonin Syndrome: Risk when combined with serotonergic agents; presents with agitation, hallucinations, tachycardia, hypertension, muscle twitching, nausea, fever, and rigidity 1

DRESS/Stevens-Johnson Syndrome: Severe cutaneous reactions with rash, fever, lymphadenopathy, blisters, or skin shedding—potentially fatal 1

Metabolic Advantages

Ziprasidone has significant advantages over other atypical antipsychotics: It causes minimal weight gain and has negligible effects on cholesterol, triglycerides, or glucose metabolism 3, 7. Patients may actually experience modest improvements in these parameters when switching from other antipsychotics 3.

Special Populations

  • Pregnancy: Discuss registry enrollment (1-866-961-2388) 1
  • Breastfeeding: Ziprasidone passes into breast milk 1
  • Elderly with dementia: Contraindicated due to increased mortality 1
  • Pediatrics: Not FDA-approved for children; only lithium has approval for bipolar disorder in youth ≥12 years 2

Clinical Pearls

  • Efficacy comparable to quetiapine and aripiprazole, but may be inferior to olanzapine or risperidone for schizophrenia 3
  • Rate of dose titration matters: Achieving 120-160 mg/day is associated with optimal symptom control and treatment persistence 3
  • The 500 kcal food requirement is non-negotiable for adequate absorption 3
  • Monitor for orthostatic hypotension, especially during initiation or dose increases 1
  • Can cause sedation; caution with driving or operating machinery 1

References

2
Guideline

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

4
Research

Ziprasidone: the fifth atypical antipsychotic.

The Annals of pharmacotherapy, 2002

Related Questions

Is ziprasidone (Geodon) 40 mg orally twice daily a strong dose?
Is ziprasidone (Geodon) available in the United States?
Can Geodon (ziprasidone) be administered three times daily?
How should I adjust ziprasidone (Geodon) dosing and manage sleepiness and blurred vision in a 28‑year‑old woman with schizoaffective disorder, bipolar type, who is currently taking ziprasidone 60 mg once daily and trazodone 100 mg nightly for sleep?
After tapering ziprasidone (Geodon) from 40 mg orally twice daily to 20 mg orally twice daily for 7 days, what is the next step‑down dosing?
In hyperkalemia management, should intravenous regular insulin be administered before intravenous dextrose?
How should a suspected Suboxone (buprenorphine‑naloxone) overdose be treated?
What are the first-line as-needed (PRN) agents for anxiety in an adult patient that do not decrease libido?
What medications or medical conditions can cause an elevated total protein level?
What is the appropriate next management step for a patient who develops pancytopenia while on methotrexate (Rheumatrex)?
Which form of systemic sclerosis (limited‑cutaneous vs diffuse‑cutaneous) is more likely to cause pulmonary hypertension and which is more likely to cause interstitial lung disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.